Market Overview

The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Share:
The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage
Related IBB
The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Healthcare And Biotechnology Dashboard - Update (Seeking Alpha)
Related MRK
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Affimed: Positive Takeaways From AFM-13 Focused R&D Day; Multiple Catalysts Ahead Including Potential Partnership With PD1/PD-L1 Company For AFM13 Combo Trial (Seeking Alpha)

Here's a roundup of top developments in the biotech space over the last 24 hours.

Scaling the Peaks

(Stocks hitting 52-week highs on Aug. 30)

  • Acceleron Pharma Inc (NASDAQ: XLRN)
  • Avid Bioservices Inc (NASDAQ: CDMO)
  • Becton Dickinson and Co (NYSE: BDX)
  • CareDx Inc (NASDAQ: CDNA)
  • Emergent Biosolutions Inc (NYSE: EBS)
  • Haemonetics Corporation (NYSE: HAE)
  • Illumina, Inc. (NASDAQ: ILMN)
  • Inogen Inc (NASDAQ: INGN)
  • Karyopharm Therapeutics Inc (NASDAQ: KPTI)
  • Medtronic PLC (NYSE: MDT)
  • Neogen Corporation (NASDAQ: NEOG)
  • Novocure Ltd (NASDAQ: NVCR)
  • Orthopediatrics Corp (NASDAQ: KIDS)
  • Reata Pharmaceuticals Inc (NASDAQ: RETA)
  • ResMed Inc. (NYSE: RMD)
  • Seattle Genetics, Inc. (NASDAQ: SGEN)
  • SurModics, Inc. (NASDAQ: SRDX)
  • Verastem Inc (NASDAQ: VSTM)
  • Xenon Pharmaceuticals Inc (NASDAQ: XENE)(reported positive pharmacodynamic Phase 1b data for XEN1101)

Down In The Dumps

(Stocks hitting 52-week lows on Aug. 30)

  • Endologix, Inc. (NASDAQ: ELGX)

See Also: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Results

Stocks In Focus

Merck's HIV Combo Drugs Wins FDA Nod

Merck & Co., Inc. (NYSE: MRK) announced the FDA has approved two HIV-1 medicines, namely Delstrigo and Pifeltro to treat HIV-1 infection in adult patients with no prior antiretroviral treatment experience.

Delstrigo combines doravirine 100 mg, lamivudine 3TC, 300mg and tenofovir disoproxil fumarate, TDF, 300mg. Meanwhile, Pifeltro is a treatment regimen combining doravirine 100mg with other antiretroviral medicines.

FDA Approves Quidel's Sofia 2 Lyme FIA

Quidel Corporation (NASDAQ: QDEL) said the FDA has granted 510(k) clearance and Clinical Laboratory Improvement Amendments waiver to market its Sofia 2 Lyme FIA to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid differential detection of human IgM and IgG antibodies to Borrelia burgdorferi from finger-stick whole blood specimens from patients suspected of B. burgdorferi infection.

Veracyte's Genomic Test Gets Medicare Coverage

Veracyte Inc (NASDAQ: VCYT) said its Envisa Genomic Classifier received a draft Medicare local coverage determination.

"The Envisia classifier, which is built on next-generation RNA sequencing and machine learning technology, is the first test to achieve this significant Medicare coverage milestone for use in diagnosing idiopathic pulmonary fibrosis," Veracyte said.

The shares advanced 5.37 percent to $12.95 in after-hours trading.

Earnings

MEI Pharma Inc (NASDAQ: MEIP) reported a fiscal-year 2018 loss of 97 cents per share compared to a profit of 7 cents per share in 2018. Revenues came in at $1.6 million.

As of June 30, 2018, the company had $102.7 million in cash, cash equivalents and short-term investments, with no outstanding debt.

Shares slipped 9.95 percent to $4.05 in after-hours trading.

Medigus Ltd. (NASDAQ: MDGS) reversed to a loss in its Q2, while its revenues fell 34 percent to $54,000.

Biopharmx Corp (NYSE: BPMX) reported a loss of 2 cents per share for its second quarter, in line with expectations.

Posted-In: Biotech Earnings News FDA Top Stories Trading Ideas Best of Benzinga

 

Related Articles (BDX + BPMX)

View Comments and Join the Discussion!

Cowen Stretches Lululemon's Target To $175 Following Strong Q2 Earnings

26 Stocks Moving In Friday's Pre-Market Session